Replies to post #534687 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Thank you. I will review the record of your published statements, but I thought that you were referring to the crossover design of the trial which was addressed in the JAMA peer review published today. The general stance of the FDA is also highly relevant as cited in the article below.

https://www.annalsofoncology.org/article/S0923-7534(22)00006-0/fulltext

https://nwbio.com/wp-content/uploads/jamaoncology_liau_2022_oi_220066_1668698380.80695.pdf